Logo image of FBIO

FORTRESS BIOTECH INC (FBIO) Stock Fundamental Analysis

NASDAQ:FBIO - Nasdaq - US34960Q3074 - Common Stock - Currency: USD

2.12  +0.16 (+8.16%)

After market: 2.17 +0.05 (+2.36%)

Fundamental Rating

2

Overall FBIO gets a fundamental rating of 2 out of 10. We evaluated FBIO against 550 industry peers in the Biotechnology industry. FBIO has a bad profitability rating. Also its financial health evaluation is rather negative. FBIO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

FBIO had negative earnings in the past year.
FBIO had a negative operating cash flow in the past year.
In the past 5 years FBIO always reported negative net income.
FBIO had a negative operating cash flow in each of the past 5 years.
FBIO Yearly Net Income VS EBIT VS OCF VS FCFFBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

FBIO has a Return On Assets of -28.50%. This is in the better half of the industry: FBIO outperforms 68.18% of its industry peers.
FBIO has a Return On Equity of -228.07%. This is in the lower half of the industry: FBIO underperforms 69.64% of its industry peers.
Industry RankSector Rank
ROA -28.5%
ROE -228.07%
ROIC N/A
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
FBIO Yearly ROA, ROE, ROICFBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

1.3 Margins

FBIO has a Gross Margin of 67.37%. This is amongst the best in the industry. FBIO outperforms 80.55% of its industry peers.
FBIO's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for FBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
FBIO Yearly Profit, Operating, Gross MarginsFBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

1

2. Health

2.1 Basic Checks

FBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
FBIO has more shares outstanding than it did 1 year ago.
FBIO has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, FBIO has a worse debt to assets ratio.
FBIO Yearly Shares OutstandingFBIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
FBIO Yearly Total Debt VS Total AssetsFBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

FBIO has an Altman-Z score of -6.80. This is a bad value and indicates that FBIO is not financially healthy and even has some risk of bankruptcy.
FBIO has a worse Altman-Z score (-6.80) than 66.36% of its industry peers.
FBIO has a Debt/Equity ratio of 2.53. This is a high value indicating a heavy dependency on external financing.
FBIO's Debt to Equity ratio of 2.53 is on the low side compared to the rest of the industry. FBIO is outperformed by 81.82% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.53
Debt/FCF N/A
Altman-Z -6.8
ROIC/WACCN/A
WACC11.7%
FBIO Yearly LT Debt VS Equity VS FCFFBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M -150M

2.3 Liquidity

A Current Ratio of 1.72 indicates that FBIO should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.72, FBIO is doing worse than 79.64% of the companies in the same industry.
A Quick Ratio of 1.55 indicates that FBIO should not have too much problems paying its short term obligations.
FBIO has a Quick ratio of 1.55. This is in the lower half of the industry: FBIO underperforms 79.82% of its industry peers.
Industry RankSector Rank
Current Ratio 1.72
Quick Ratio 1.55
FBIO Yearly Current Assets VS Current LiabilitesFBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

FBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.29%, which is quite impressive.
The Revenue for FBIO has decreased by -32.11% in the past year. This is quite bad
The Revenue has been growing by 9.50% on average over the past years. This is quite good.
EPS 1Y (TTM)60.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.4%
Revenue 1Y (TTM)-32.11%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%0.84%

3.2 Future

The Earnings Per Share is expected to grow by 22.90% on average over the next years. This is a very strong growth
FBIO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 64.44% yearly.
EPS Next Y56.33%
EPS Next 2Y32.01%
EPS Next 3Y22.9%
EPS Next 5YN/A
Revenue Next Year45.64%
Revenue Next 2Y45.19%
Revenue Next 3Y50.04%
Revenue Next 5Y64.44%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
FBIO Yearly Revenue VS EstimatesFBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
FBIO Yearly EPS VS EstimatesFBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FBIO. In the last year negative earnings were reported.
Also next year FBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FBIO Price Earnings VS Forward Price EarningsFBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FBIO Per share dataFBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as FBIO's earnings are expected to grow with 22.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.01%
EPS Next 3Y22.9%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FBIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FORTRESS BIOTECH INC

NASDAQ:FBIO (8/15/2025, 8:18:30 PM)

After market: 2.17 +0.05 (+2.36%)

2.12

+0.16 (+8.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-12 2025-11-12/amc
Inst Owners13.05%
Inst Owner Change-25.22%
Ins Owners15%
Ins Owner Change0.06%
Market Cap62.69M
Analysts82.5
Price Target15.64 (637.74%)
Short Float %13.41%
Short Ratio14.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.22
Dividend Growth(5Y)-17.74%
DP-5.3%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.66%
Min EPS beat(2)2.39%
Max EPS beat(2)4.93%
EPS beat(4)3
Avg EPS beat(4)5.9%
Min EPS beat(4)-25.23%
Max EPS beat(4)41.5%
EPS beat(8)6
Avg EPS beat(8)21.16%
EPS beat(12)7
Avg EPS beat(12)11.16%
EPS beat(16)8
Avg EPS beat(16)-21.02%
Revenue beat(2)1
Avg Revenue beat(2)0.9%
Min Revenue beat(2)-9.04%
Max Revenue beat(2)10.85%
Revenue beat(4)1
Avg Revenue beat(4)-13.7%
Min Revenue beat(4)-55.48%
Max Revenue beat(4)10.85%
Revenue beat(8)4
Avg Revenue beat(8)13.76%
Revenue beat(12)4
Avg Revenue beat(12)0.89%
Revenue beat(16)7
Avg Revenue beat(16)-0.47%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)19.1%
EPS NY rev (1m)0%
EPS NY rev (3m)12.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-7.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.08
P/FCF N/A
P/OCF N/A
P/B 2.82
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.72
EYN/A
EPS(NY)-0.84
Fwd EYN/A
FCF(TTM)-3.02
FCFYN/A
OCF(TTM)-2.51
OCFYN/A
SpS1.95
BVpS0.75
TBVpS-0.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.5%
ROE -228.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.37%
FCFM N/A
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
F-Score3
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 2.53
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.72
Quick Ratio 1.55
Altman-Z -6.8
F-Score3
WACC11.7%
ROIC/WACCN/A
Cap/Depr(3y)152.42%
Cap/Depr(5y)127.86%
Cap/Sales(3y)11.86%
Cap/Sales(5y)9.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.4%
EPS Next Y56.33%
EPS Next 2Y32.01%
EPS Next 3Y22.9%
EPS Next 5YN/A
Revenue 1Y (TTM)-32.11%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%0.84%
Revenue Next Year45.64%
Revenue Next 2Y45.19%
Revenue Next 3Y50.04%
Revenue Next 5Y64.44%
EBIT growth 1Y17.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year62.35%
EBIT Next 3Y22.94%
EBIT Next 5YN/A
FCF growth 1Y49.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.69%
OCF growth 3YN/A
OCF growth 5YN/A